Novo Nordisk has made its smart insulin pens available in the UK ... The Danish pharma is trying to stay ahead of arch rivals Eli Lilly and Sanofi in an increasingly competitive insulin market ...

But it looks unlikely that Lilly will be able to maintain this with the launch of Humalog, which is available in vial form or as a disposable pen. Sanofi fights back This represents Sanofi's first ...

injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% ...

In 2023, the global disposable pen injectors market is expected to be worth USD 25.5 billion. The market is expected to reach USD 54.4 billion by 2033, expanding at a 7.9% CAGR throughout the forecast ...

With Wegovy now playing catch-up and CagriSema failing to shake up the game, Novo is staring down a serious challenge from Lilly, which is running away with the weight-loss drug crown. So ...

What do Trump's tariffs have to do with Eli Lilly? Novo Nordisk (NYSE: NVO) is based in Denmark, which is one of the countries on Trump's list for especially high tariffs. Novo Nordisk's type 2 ...

Trump has threatened to impose "very high" tariffs on Denmark if it doesn't sell Greenland to the U.S. These tariffs could cause the prices of Novo Nordisk's diabetes and obesity drugs to increase.